Article Text

Download PDFPDF

P120/221  Can the novel pRELAX traction maneuver be the long-awaited solution for the treatment of posthemorrhagic cerebral vasospasm ?
  1. Ali Khanafer1;2,
  2. Von Gottberg Philipp3,
  3. Victoria Hellstern4,
  4. Alexandru Cimpoca1,
  5. Oliver Ganslandt5,
  6. Hans Henkes3
  1. 1Klinikum Stuttgart – Katharinenhospital , Neuroradiologische Klinik, Neurozentrum, Stuttgart, Germany
  2. 2Klinikum Stuttgart – Katharinenhospital Institut für Krankenhaushygiene (Klinikum Stuttgart), Neuroradiologische Klinik, Neurozentrum, Stuttgart, Germany
  3. 3Klinikum Stuttgart – Katharinenhospital, Neuroradiologische Klinik, Neurozentrum, Stuttgart, Germany
  4. 4Klinikum Stuttgart – Katharinenhospital, Stuttgart, Germany
  5. 5Klinikum Stuttgart – Katharinenhospital, Neurochirurgische Klinik, Neurozentrum, Stuttgart, Germany


Introduction Cerebral vasospasm (CVS) is a frequent complication following subarachnoid hemorrhage (SAH). The most interventional and pharmacological measures are only effective for short periods.

Recently, studies have shown a possibly beneficial effect of the treatment of CVS following SAH through stent-retriever devices. We report our experience with the new pRELAX traction maneuver and device in the treatment of CVS.

Aim of Study Our aim is to show that the pRELAX traction maneuver is both safe and effective in our small experience.

Methods We treated six patients suffering from posthemorrhagic CVS using pRELAX Traction Maneuver.

We temporarily deployed the pRELAX device into CVS affected vessels and pulled it back unfolded into the internal carotid artery; in a technique comparable to endovascular thrombectomy.

Angiographic results, periprocedural complications and angiographic follow-up data were recorded.

Results Six patients and thirteen vessels were included (8 middle cerebral artery; 5 intradural internal carotid artery). There were no periprocedural complications and all vessels showed significant angiographic improvement already during the treatment. None of the treated vessels showed recurrent CVS requiring further endovascular treatment. No new ischemia were found in the treated vessels territories and no vascular injury was seen on follow-up angiographies.

Conclusion The treatment of CVS with the new pRELAX traction maneuver showed promising results in our experience, at a low risk and with favorable in-hospital course of the patients. Since the treatment options of CVS following SAH are limited, this initiative may pose a long sought measure to prevent ischemic complications for patients surviving SAH.

Disclosure of Interest Ali Khanafer:

Nothing to disclose

Philpp von Gottberg:

Nothing to disclose

Victoria Hellstern:

Nothing to disclose

Alexandru Cimpoca:

Nothing to disclose

Oliver Ganslandt:

Nothing to disclose

Hans Henkes is a co-founder and shareholder of CONTARA GmbH

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.